NCT03556228 2025-12-11VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaVM Oncology, LLCPhase 1/2 Recruiting242 enrolled
NCT05941507 2025-09-24A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid TumorsLigaChem Biosciences, Inc.Phase 1/2 Recruiting300 enrolled